Warner Bros. Entertainment Group of Companies
Dc Entertainment
Bloom Film Jun 2015 - Aug 2017
Coordinator
Bloom Film May 2014 - May 2015
Executive Assistant To Alex Walton
Double Feature Films Oct 2013 - May 2014
Executive Assistant To Stacey Sher
A Management May 2012 - Jul 2013
Executive Assistant To Chief Executive Officer and Talent Manager
Education:
New York University 2012
Master of Fine Arts, Masters, Film and Television, Television, Film
Nyu Tisch Art and Public Policy 2008 - 2012
Master of Fine Arts, Masters, Fine Arts, Film and Television, Television, Film
National University Preparatory School For Overseas Chinese Students 2007 - 2007
University of Missouri 2006
University of Missouri - Columbia 2003 - 2006
Bachelors, Broadcast Journalism, Journalism
University of California, Santa Cruz 2002 - 2003
University of Missouri
Skills:
Film Avid Short Films Final Cut Pro Video Video Production Producing Video Editing Television Documentaries Storytelling Videography Avid Media Composer Camera Broadcast Journalism Social Media Creative Writing Web Video Film Production Editing Screenwriting Broadcast New Media Media Production Final Cut Studio Multimedia Directing
Interests:
Christianity Cooking Exercise Investing Traveling Sweepstakes Electronics Home Improvement Reading Sports Music Golf Family Values Travel Movies Home Decoration
Dennis G. Ballinger - Menlo CA John Ford - San Mateo CA Alice Suk-Yue Ho - Union City CA Hai Shan Lin - Castro Valley CA Ann M. Pace - Scotts Valley CA
The present invention provides novel nucleic acids encoding IL-1 Hy2, a novel member of the Interleukin-1 Receptor Antagonist family, the novel polypeptides encoded by these nucleic acids and uses of these and related products.
Kevin W. Moore - Palo Alto CA Ying Liu - Mountain View CA Alice Suk-Yue Ho - Milpitas CA Bazan Fernando J. - Menlo Park CA Jimmy C. Tan - Edison NJ Chuan-Chu Chou - Westfield NJ
Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.
John Ford - San Mateo CA Alice Suk-Yue Ho - Union City CA
Assignee:
Hyseq, Inc. - Sunnyvale CA
International Classification:
A61K 4500
US Classification:
424 852, 514 2, 530351
Abstract:
The present invention provides novel therapeutic methods of administering an amount of IL-1Ra to treat IL-18 related disorders. Specifically, the method involves treating IL-18 related disorders such as liver injury, hepatis, hemophagocytic lymphohistiocytosis, multiple sclerosis, tumors, cytotoxicity resulting from antitumor therapy, or other autoimmune disorders with a therapeutically effective amount of IL-1ra, and optionally measuring IFN- and IL-18 activity from human samples.
Interleukinâ1 Receptor Antagonist And Uses Thereof
John Ford - San Mateo CA Alice Suk-Yue Ho - Union City CA Ann Pace - Scotts Valley CA
Assignee:
Hyseq, Inc. - Sunnyvale CA
International Classification:
C07H 2104
US Classification:
536 243, 4352872, 4352883, 4352884, 536 231
Abstract:
The present invention provides novel nucleic acids, the novel polypeptide sequences encoded by these nucleic acids and uses thereof. These novel polynucleotide and polypeptide sequences were determined to be a novel Interleukin-1 Receptor Antagonist.
Dennis Ballinger - Menlo Park CA, US John Ford - San Diego CA, US Alice Ho - Palo Alto CA, US Haishan Lin - Castro Valley CA, US Ann Pace - Scotts Valley CA, US Nancy Mize - Mountain View CA, US
International Classification:
A61K038/17 C07K014/435
US Classification:
514/012000, 530/350000
Abstract:
The present invention provides machine readable storage media comprising a three-dimensional representation of Interleukin-1 Hy2 (IL-1Hy2), useful for designing and producing modulators of its activity and IL-1 Hy2 variants, and therapeutic uses thereof. The present invention also provides novel nucleic acids encoding IL-1 Hy2, the novel polypeptides encoded by these nucleic acids and uses of these and related products.
Treatment Of Immune Disorders And B Cell Disorders
Alice Ho - Palo Alto CA, US John Ford - San Diego CA, US Hai-Shan Lin - Castro Valley CA, US Fabio Rupp - Sunnyvale CA, US
International Classification:
A61K039/395
US Classification:
424/145100
Abstract:
The present invention provides materials and methods of using compositions comprising the IL-1Hy1 polypeptide or inhibitors of IL-1Hy1 activity for treatment of immune cell disorders.
Methods And Materials Relating To Prothrombinase-Like Polypeptides And Polynucleotides
Bryan Boyle - San Francisco CA, US Alice Ho - Palo alto CA, US PING Zhou - Cupertino CA, US Nancy Mize - Mountain View CA, US Chiaoyun Kuo - San Jose CA, US Matthew Arterburn - San Jose CA, US Y. Tom Tang - San Jose CA, US Chenghua Liu - San Jose CA, US Radoje Drmanac - Palo Alto CA, US
The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel secreted prothrombinase-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human ovary (Hyseq clone identification numbers 773565 (SEQ ID NO: 1) and 7727065 (SEQ ID NO: 11)). Other aspects of the invention include vectors containing processes for producing novel secreted prothrombinase-like polypeptides, and antibodies specific for such polypeptides.
Kevin W. Moore - Palo Alto CA Ying Liu - Mountain View CA Alice Suk-Yue Ho - Milpitas CA J. Fernando Bazan - Menlo Park CA Jimmy C. Tan - Edison NJ Chuan-Chu Chou - Westfield NJ
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C12N 1512
US Classification:
435 691
Abstract:
Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.